title: Enhanced serum concentrations of Ara-C using suppositories containing tetrahydrouridine as a deamination inhibitor of Ara-C.
abstract: Rectal bioavailability of Ara-C (serum AUC 4 h: 65 micrograms h-1 ml-1) administered in a suppository formulation containing tetrahydrouridine (a deamination inhibitor) and sodium salicylate (an adjuvant) to dogs was better than that from a suppository formulation without tetrahydrouridine (serum AUC 4 h: 18 micrograms h-1 ml-1).
authors.forename: G G
authors.initials: GG
authors.lastname: Liversidge
authors.forename: T
authors.initials: T
authors.lastname: Nishihata
authors.forename: K K
authors.initials: KK
authors.lastname: Engle
authors.forename: T
authors.initials: T
authors.lastname: Higuchi
mesh_terms: D000818:Animals; D001086:Arabinofuranosyluracil / Q000097:blood; D001682:Biological Availability; D003561:Cytarabine / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000097:blood*; D003641:Deamination; D004285:Dogs; D007700:Kinetics; D012459:Salicylates / Q000494:pharmacology; D020156:Salicylic Acid; D013488:Suppositories; D013767:Tetrahydrouridine / Q000494:pharmacology*; D014529:Uridine / Q000031:analogs & derivatives*
chemical_list: D012459:Salicylates; D013488:Suppositories; D003561:Cytarabine; D013767:Tetrahydrouridine; D001086:Arabinofuranosyluracil; D020156:Salicylic Acid; D014529:Uridine